Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
About Index
Index
By TNW
Log in
Register
Stoke Therapeutics
3197
Stoke Therapeutics
Technology
Biotechnology
Health Care
Medical
Therapeutics
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
Suggest edits
Type
B2b
Founded
2017
Raised
$130M
Follow us
Companies in the same industry
Cedilla Therapeutics
Gotham Therapeutics
Imara, Inc.
Artax Biopharma
Engrail Therapeutics
MiNA Therapeutics
Federation Bio
Neuroglee Therapeutics
Care Point Software
Mirna Therapeutics, Inc.
Alexa global traffic share
Overview
Funding
2
Add info
Latest funding
$90,000,000
Venture capital (Series B) - 2018
RTW Investments
$40,000,000
Venture capital (Series A) - 2018
Apple Tree Partners
Team Size
10+
Employees
I work here
Location
United States
Headquarters
Explore United States
$90,000,000
Venture capital (Series B)
FinSMEs
,
PE HUB
Stoke Therapeutics Raises $90M in Series B Financing
Funding
Health
FinSMEs
Stoke Therapeutics Raises $40M in Series A Financing
Science
Health
Funding